Public Library of Science
Browse

ACE-CONVERT clinical trial plan.

Download (1.62 MB)
journal contribution
posted on 2023-03-14, 17:27 authored by Marye J. Gleva, Joseph Sullivan, Thomas C. Crawford, Greg Walcott, Ulrika Birgersdotter-Green, Kelley R. Branch, Rahul N. Doshi, Kaisa Kivilaid, Kelly Brennan, Ron K. Rowbotham, Laura M. Gustavson, Jeanne E. Poole

Introduction

The wearable cardioverter defibrillator (WCD) is used to protect patients at risk for sudden cardiac arrest. We examined defibrillation efficacy and safety of a biphasic truncated exponential waveform designed for use in a contemporary WCD in three animal studies and a human study.

Methods

Animal (swine) studies:

#1: Efficacy comparison of a 170J BTE waveform (SHOCK A) to a 150J BTE waveform (SHOCK B) that approximates another commercially available waveform. Primary endpoint first shock success rate.

#2: Efficacy comparison of the two waveforms at attenuated charge voltages in swine at three prespecified impedances. Primary endpoint first shock success rate.

#3: Safety comparison of SHOCK A and SHOCK B in swine. Primary endpoint cardiac biomarker level changes baseline to 6 and 24 hours post-shock.

Human Study: Efficacy comparison of SHOCK A to prespecified goal and safety evaluation. Primary endpoint cumulative first and second shock success rate. Safety endpoint adverse events.

Results

Animal Studies

#1: 120 VF episodes in six swine. First shock success rates for SHOCK A and SHOCK B were 100%; SHOCK A non-inferior to SHOCK B (entire 95% CI of rate difference above -10% margin, p < .001).

#2: 2,160 VF episodes in thirty-six swine. Attenuated SHOCK A was non-inferior to attenuated SHOCK B at each impedance (entire 95% CI of rate difference above -10% margin, p < .001).

#3: Ten swine, five shocked five times each with SHOCK A, five shocked five times each with SHOCK B. No significant difference in troponin I (p = 0.658) or creatine phosphokinase (p = 0.855) changes from baseline between SHOCK A and SHOCK B.

Human Study: Thirteen patients, 100% VF conversion rate. Mild skin irritation from adhesive defibrillation pads in three patients.

Conclusions

The BTE waveform effectively and safely terminated induced VF in swine and a small sample in humans.

Trial registration

Human study clinical trial registration: URL: https://clinicaltrials.gov; Unique identifier: NCT04132466.

History